Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in your watchlist
Most Trending
+12.90%
-18.60%
-8.88%
+9.09%
+5.34%
AMGN
Amgen
$287.71
Chart
$300.08 (-4.12%)
$290.33 (-0.90%)
$291.09 (-1.16%)
$335.26 (-14.18%)
FIND US ON
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
+12.90%
-18.60%
-8.88%
+9.09%
+5.34%
AMGN
Amgen
Current Price
$287.71
Login to view Amgen (AMGN) recommendation from the last 90 days from financial news and social media.
Chart
$300.08 (-4.12%)
$290.33 (-0.90%)
$291.09 (-1.16%)
$335.26 (-14.18%)
AMGN has Low Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk
AMGN Latest Analysis
Veeva annonce sa collaboration avec une société de biotechnologie mondiale pour continuer daccélérer linnovation en matière dessais cliniques. BARCELONE Espagne 28 août 2025 /PRNewswire/ -- Veeva Systems (NYSE : VEEV) a annoncé aujourdhui une collaboration avec Amgen pour faire progresser linnovation en matière dessais cliniques. En tant que chef de file mondial de la biotechnologie Amgen utilisera la Veeva Clinical...
Thu Aug 28, 2025
Veeva partners with Amgen to speed up clinical trials.
Thu Aug 28, 2025
BeOne Cashes In On Amgens Cancer Drug Royalties In Multibillion-Dollar Pharma Tie-Up. ) on Monday agreed to sell its royalty rights on the worldwide sales excluding China of ) Imdelltra (tarlatamab-dlle) for up to $950 million to ).Under the terms of the agreement BeOne will receive an upfront payment of $885 million with the option to sell remaining royalties within 12 months .BeOne will share in a portion of the royalty on annual sales above $1.5 billion and will maintain royalty and all other
Mon Aug 25, 2025
Deep Dive Into Amgen Stock: Analyst Perspectives (9 Ratings). Amgen (NASDAQ:) has been analyzed by 9 analysts in the last three months revealing a diverse range of perspectives from ish to bearish.The table below offers a condensed view of their recent ratings showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.0261001000003000121000100Analysts have set 12-month price targets for Amgen revealing an average target of $314.11 a high estimate of $342.
Mon Aug 25, 2025
Amgen: FDA Broadens Approved Use Of Repatha . (RTTNews) - Amgen (AMGN) announced the FDA has broadened the approved use of Repatha or evolocumab to include adults at increased risk for major adverse cardiovascular events due to uncontrolled low-density lipoprotein cholesterol. The update removes a prior requirement for a pat
Mon Aug 25, 2025
Ex-Dividend Reminder: Amgen United States Physical Therapy and Dynex Capital . Looking at the universe of stocks we cover at Dividend Channel on 8/22/25 Amgen Inc (Symbol: AMGN) United States Physical Therapy Inc. (Symbol: USPH) and Dynex Capital Inc (Symbol: DX) will all trade ex-dividend for their respective upcoming dividends. Amgen Inc will pay its quarter
Wed Aug 20, 2025
Gastric Cancer Market on Growth Trajectory: Novel Therapies Drive Momentum Through 2034 | DelveInsight. Gastric Cancer Market on Growth Trajectory: Novel Therapies Drive Momentum Through 2034 |. DelveInsight The outlook for the gastric cancer treatment market appears favorable fueled by progress in targeted therapies and immunotherapies. Traditionally platinum-based chemotherapy has served as the primary treatment for early-stage gastric cancer underscoring the demand for more effective alte
Mon Aug 11, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
AMGN Stock trends
AMGN Stock performance
AMGN Stock analysis
AMGN investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
Hover over the category for more information
Overview
Trending
Screener
Insights
Top Rated
Momentum
Earnings